<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/DDD14154-81FB-417E-81AA-AAEA066ECA04"><gtr:id>DDD14154-81FB-417E-81AA-AAEA066ECA04</gtr:id><gtr:name>The Wellcome Trust  Sanger Institute</gtr:name><gtr:address><gtr:line1>Wellcome Trust Genome Campus</gtr:line1><gtr:line2>Hinxton</gtr:line2><gtr:postCode>CB10 1SA</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/961756BF-E31F-4A13-836F-0A09BA02385C"><gtr:id>961756BF-E31F-4A13-836F-0A09BA02385C</gtr:id><gtr:name>University of Exeter</gtr:name><gtr:department>Peninsula Medical School</gtr:department><gtr:address><gtr:line1>University of Exeter</gtr:line1><gtr:line2>Clydesdale House</gtr:line2><gtr:line3>Clydesdale Road</gtr:line3><gtr:line4>Exeter</gtr:line4><gtr:postCode>EX4 4QX</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/961756BF-E31F-4A13-836F-0A09BA02385C"><gtr:id>961756BF-E31F-4A13-836F-0A09BA02385C</gtr:id><gtr:name>University of Exeter</gtr:name><gtr:address><gtr:line1>University of Exeter</gtr:line1><gtr:line2>Clydesdale House</gtr:line2><gtr:line3>Clydesdale Road</gtr:line3><gtr:line4>Exeter</gtr:line4><gtr:postCode>EX4 4QX</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/DDD14154-81FB-417E-81AA-AAEA066ECA04"><gtr:id>DDD14154-81FB-417E-81AA-AAEA066ECA04</gtr:id><gtr:name>The Wellcome Trust  Sanger Institute</gtr:name><gtr:address><gtr:line1>Wellcome Trust Genome Campus</gtr:line1><gtr:line2>Hinxton</gtr:line2><gtr:postCode>CB10 1SA</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/F664E697-5681-4CA8-9324-0C97321CDB72"><gtr:id>F664E697-5681-4CA8-9324-0C97321CDB72</gtr:id><gtr:firstName>Robin</gtr:firstName><gtr:surname>Murray</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/81FA5C0D-15FB-45DF-95B7-4C8D9F28AA89"><gtr:id>81FA5C0D-15FB-45DF-95B7-4C8D9F28AA89</gtr:id><gtr:firstName>Jonathan</gtr:firstName><gtr:surname>Mill</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/1A01FA37-E0D7-4F62-9F22-E7EE47DBF21C"><gtr:id>1A01FA37-E0D7-4F62-9F22-E7EE47DBF21C</gtr:id><gtr:firstName>Leonard</gtr:firstName><gtr:otherNames>Cornelis</gtr:otherNames><gtr:surname>Schalkwyk</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/834BE94F-BC05-4996-8A50-403EA71E549A"><gtr:id>834BE94F-BC05-4996-8A50-403EA71E549A</gtr:id><gtr:firstName>Gerome</gtr:firstName><gtr:otherNames>Daniel</gtr:otherNames><gtr:surname>Breen</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=MR%2FK013807%2F1"><gtr:id>2A152B5E-59F1-4076-B060-B2DB97BF2721</gtr:id><gtr:title>Methylomic profiling in schizophrenia: towards an integrated genetic-epigenetic approach</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/K013807/1</gtr:grantReference><gtr:abstractText>Schizophrenia is a severe psychiatric disorder, characterized by psychotic symptoms, delusions and hallucinations, disorganisation, dysfunctional affective responses, and altered cognitive functioning. The social and economic consequences of schizophrenia are severe, eclipsing those of many other illnesses. With a lifetime prevalence rate of ~1%, schizophrenia contributes significantly to the global burden of disease, ranking among the top ten causes of disability in developed countries worldwide. Current approaches to understanding the causes of schizophrenia have focused primarily on uncovering a genetic contribution to the disorder, although identifying risk variants has not been straightforward. Furthermore, there is considerable heterogeneity across studies and the mechanism behind the action of genetic risk variants remains largely unknown. Despite considerable research effort, therefore, we are remain no closer to understanding the precise aetiology of SZ and a long way from realising the post-genomic promises of novel diagnostic and therapeutic strategies. 

Sequencing the genome was, however, only the first step in our quest to understand how genes are expressed and regulated. Sitting above the DNA sequence is a second layer of information (the 'epigenome') that mediates the regulation of when and where genes are functionally transcribed. Unlike the DNA sequence, which is stable and strongly conserved, epigenetic processes can be highly dynamic: not only are they developmentally-regulated, but they can also be modified by exposure to a range of external environmental factors and stochastic events in the cell. 

This study aims, for the first time, to systematically examine the role of epigenetic processes in schizophrenia, focusing on DNA methylation, a chemical modification to DNA that can directly influence gene transcription and function. We will use cutting-edge methods to examine genome-wide patterns of DNA methylation in several unique collections of samples. First, we will use a large collaborative collection of schizophrenia patients and controls. These samples have already been extensively studied at the genetic level, enabling us to undertake an integrated genetic-epigenetic approach to schizophrenia. Second, we will examine epigenetic differences within genetically-identical monozygotic twin-pairs, where one twin has schizophrenia and the other does not. Third, we will examine differences in brain tissue taken post-mortem from patients with schizophrenia. Finally, we will assess epigenetic changes across specific regions of the genome in individuals at high-risk for developing schizophrenia, tracking changes in DNA methylation with disease onset. 

Our proposed integrated genetic-epigenetic approach brings together a world-class group of epigeneticists, geneticists, clinicians and bioinformaticians with the ultimate goal of identifying peripheral epigenetic biomarkers for schizophrenia and transforming diagnostic, therapeutic, and future aetiological approaches to the disease.</gtr:abstractText><gtr:technicalSummary>We propose a comprehensive genome-wide analysis of epigenetic dysfunction associated with schizophrenia (SZ) using cutting-edge methodologies to identify novel pathways involved in pathogenesis. We will examine genome-wide patterns of DNA methylation in a unique collection of samples. First, via collaboration with research groups involved in the UK10K consortium, we will undertake methylomic analysis using the Illumina Infinium 450K array in SZ samples (n=1700) and matched controls (n=1700) from ongoing genome-wide association study (GWAS) and exome sequencing projects, enabling us to perform an integrated epigenetic-genetic analytical strategy and representing the largest epigenome-wide association study yet undertaken. Specific SZ-associated differentially methylated regions (DMRs) will be verified and subsequently replicated in another set of samples using the Sequenom EpiTYPER platform and bisulfite pyrosequencing. Validated DMRs will also be examined longitudinally in a high-risk prodromal cohort to investigate epigenetic changes associated with the transition into disease. Second, we will examine genome-wide patterns of DNA methylation in MZ twin-pairs discordant for SZ using the largest collection of such samples ever assessed. This will enable us to examine the epigenome independent of any underlying genomic sequence variation and allow us to fully control for factors such as age, sex and the early (pre- and peri-natal) environment while providing further independent validation/replication for SZ-associated regions implicated in Aim 1. Third, we will use post-mortem brain samples obtained from SZ cases and controls to examine the extent to which disease-associated epigenetic marks detected in the periphery reflect changes occurring in functionally-relevant tissues. A key element of data analysis will involve the integration of epigenetic information with GWAS data, exome sequencing and other clinical/demographic data using novel methods developed in our lab.</gtr:technicalSummary><gtr:potentialImpactText>In addition to other scientists (especially other and research groups investigating the aetiology of schizophrenia) the results of this project have the potential to impact on a number of other beneficiaries. These include patients suffering from schizophrenia, the pharmaceutical industry, health service providers, and academic groups investigating the causes of other complex disease phenotypes.

The social and economic consequences of schizophrenia are severe, eclipsing those of many other mental and somatic illnesses. With a lifetime prevalence rate of ~1%, the disorder contributes significantly to the global burden of disease, ranking among the top ten causes of disability in developed countries worldwide. Importantly, there is no cure for schizophrenia, and available treatments are often inefficient and characterized by severe side-effects. Given the dynamic and potentially-reversible nature of the epigenome, the outputs from this research could potentially nominate new targets for drug development for the treatment of schizophrenia. A number of pharmaceutical companies are actively developing so-called &amp;quot;epigenetic drugs&amp;quot; and could rapidly take advantage of these outputs. Our data may also highlight novel neurobiological pathways involved in schizophrenia, again stimulating the development of novel therapeutic interventions. Developing new treatments for schizophrenia will have subsequent benefits to the family and friends of affected individuals, and potentially boost the economy by enabling affected individuals to return to work.

Another positive output of this research may be the identification of potential blood biomarkers for risk of schizophrenia, which could have important public health implications. For example, if we are able to detect epigenetic changes in our high-risk prodromal samples, this could be used to develop tests for the disease before symptoms become manifest, resulting in more relevant and targeted interventions. Identifying biological correlates of schizophrenia may also help remove some of the stigma associated with the disease.

Finally, we hope that our novel integrated genetic-epigenetic approach to schizophrenia may stimulate similar research strategies to be adopted by academics working in the context of other complex disease phenotypes.</gtr:potentialImpactText><gtr:fund><gtr:end>2016-08-30</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2013-08-31</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>835855</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Wellcome Trust Sanger Institute</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Medical Research Council (MRC) Integrative Epidemiology Unit at the University of Bristol</gtr:department><gtr:description>GW4 Epigenetics Network</gtr:description><gtr:id>D42EEE6B-9B7A-4DD2-960D-7CE1E7F1EEC4</gtr:id><gtr:impact>We have agreed to share resources and expertise. Several collaborative research projects related to the goals of our MRC award have been established.</gtr:impact><gtr:partnerContribution>We participated in a two-day workshop, that has spawned several collaborative projects</gtr:partnerContribution><gtr:piContribution>As part of the GW4 partnership (between Universities of Exeter, Bristol, Cardiff and Bath) we were funded to establish a network of researchers focussed on epigenetic studies in mental illness.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Bristol</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Genetics of DNA Methylation Consortium (GoDMC)</gtr:description><gtr:id>CCBCC8AB-7B61-4DF6-AC7A-BE5CA13A2D78</gtr:id><gtr:impact>We are undertaking a large, collaborative meta-analysis. Data will be written-up as a publication in the next year.</gtr:impact><gtr:partnerContribution>Data sharing and collaborative analyses</gtr:partnerContribution><gtr:piContribution>This is a collaborative consortium that is aiming to identify genetic influences on DNA methylation.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London (KCL)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Genetics of DNA Methylation Consortium (GoDMC)</gtr:description><gtr:id>5982EBBD-5DF4-472D-97AD-57E81DA8B58B</gtr:id><gtr:impact>We are undertaking a large, collaborative meta-analysis. Data will be written-up as a publication in the next year.</gtr:impact><gtr:partnerContribution>Data sharing and collaborative analyses</gtr:partnerContribution><gtr:piContribution>This is a collaborative consortium that is aiming to identify genetic influences on DNA methylation.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Two selected oral presentations at the Wellcome Trust Epigenomics of Common Diseases meeting</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>84D7DD44-4AD7-4444-97E7-06FFDCD1FDCC</gtr:id><gtr:impact>We had two platforms presenting work from this project at the Wellcome Trust Epigenomics of Common Diseases meeting.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:url>https://coursesandconferences.wellcomegenomecampus.org/events/item.aspx?e=594</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation at the World Congress of Psychiatric Genetics (Copenhagen, October 2014)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>2C0A12BA-5F45-4DC8-A123-E15F8700290F</gtr:id><gtr:impact>My presentation was selected as a plenary oral presentation and resulted in positive feedback. We are following-up potential new collaborations.

Talk was discussed in social media (twitter), and we have received requests for further information on our study.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://2014.ispg.net/wp-content/uploads/2014/09/WCPG-Oral-Presentation-Abstracts-FINAL.pdf</gtr:url></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Three posters at World Congress of Psychiatric Genetics, Toronto</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>6567A933-10F5-4600-867D-71BAEDD78062</gtr:id><gtr:impact>Work resulting from this grant was presented both in poster format and orally (see other entry) at the WCPG meeting. There was considerable interest in our findings amongst the international research attendees.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:url>http://2015.ispg.net/</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Coverage of schizophrenia epigenetics study</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>ABCC5CA5-EC6D-48A1-B79D-F20CB1DC3353</gtr:id><gtr:impact>Interview with Epigenie - an epigenetics news website. They ran a news feature on our recent Genome Biology article that resulted from our MRC grant.

Increased awareness of our research, and contact by other scientists working on epigenetic dysfunction in schizophrenia.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://epigenie.com/developmental-origin-of-schizophrenia-associated-dna-methylation/</gtr:url></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Interview with New Scientist</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>D7FEE84A-88FD-4F9E-9093-5C149417E5E4</gtr:id><gtr:impact>I have been interviewed for a forthcoming piece on epigenetics in disease.

The journalist is currently writing an article.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Feature article on our research in British Neuroscience Association (BNA) Newsletter</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>5422169A-EB73-4F4F-8422-AD09BE4FFC1C</gtr:id><gtr:impact>The BNA interviewed me, and wrote a feature article on our work.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:url>https://www.bna.org.uk/publications/bna-bulletin/</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited talk at the &quot;Epigenomics 2016&quot; meeting in Puerto Rico</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>797459DF-D2AA-4932-89E7-61CE1CEE8A08</gtr:id><gtr:impact>The National Institutes of Health invited myself and two team members to Puerto Rico to speak at a large international Epigenomics meeting where I presented our schizophrenia research. There was considerable interest and several new collaborations have arisen from this meeting.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:url>http://epigenomics2016.org</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited presentations at Birkbeck, KCL, Oxford, Exeter Uni, Bristol Uni</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>6D6B8C70-56A2-46ED-93A0-E6CD5AE9794B</gtr:id><gtr:impact>I have given invited seminars presenting work from this project at several Universities.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2015,2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Two posters at World Congress of Psychiatric Genetics (Copenhagen, October 2014)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>8C1F75A3-615A-4BF0-8534-D8EE0B5F2454</gtr:id><gtr:impact>Posters sparked considerable interest in our work on schizophrenia-discordant monozygotic twins, and the integration of epigenetic and genetic information.

Via a new collaboration, additional twin-pairs are being recruited into our study.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://2014.ispg.net</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Epigenomic and transcriptomic signatures of a Klinefelter syndrome (47,XXY) karyotype in the brain. Oral presentation as an invited speaker at the 2nd International Workshop on Klinefelter Syndrome. M?nster, Germany. 10th - 12th March 2016.</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>114C3BA4-D578-444C-8EAF-D35CA576905B</gtr:id><gtr:impact>We were invited to present out genomic work on XXY brain at an international meeting. We have instigated a collaboration based on interactions at this meeting.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited talk at EMBO Epigenetics of Neural (dys)function meeting in Braga, Portugal</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>C42126E4-5AD5-492D-97D2-9A81F441E881</gtr:id><gtr:impact>Increased interest in our research, including approaches by potential PhD students.

Possible student exchanges arranged.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://events.embo.org/14-epigenetics/</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation at the Wellcome Trust Epigenomics of Common Diseases meeting</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>1E35B5C5-641C-40DF-A687-9A0D53B8D366</gtr:id><gtr:impact>My talk stimulated considerable discussion and interest.

We established a collaboration with a group who will work to replicate our findings.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>https://registration.hinxton.wellcome.ac.uk/display_info.asp?id=441</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Oral presentation at the Wellcome Trust Genomics of Brain Disorders Meeting</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>05A13AF9-D436-40F1-A6E2-27E7EEFCAE90</gtr:id><gtr:impact>Data from our schizophrenia was presented in a platform session. It stimulated positive feedback and additional discussion.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:url>http://conf.hinxton.wellcome.ac.uk/advancedcourses/Genomics_of_Brain_Disorders_draft_programmeV11website.pdf</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Epigenetic dynamics of Human Brain Development. Invited Oral presentation. Birkbeck College, 3rd July.</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>259C624D-3093-4760-8390-8BDCD36C2109</gtr:id><gtr:impact>Departmental presentation -- stimulated much interest and debate.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>NARSAD/BBRF DISTINGUISHED INVESTIGATOR AWARD</gtr:description><gtr:end>2017-03-02</gtr:end><gtr:fundingOrg>Brain &amp; Behaviour Research Foundation</gtr:fundingOrg><gtr:id>F6BA8E61-7448-4D74-BFB0-11E6934EFC1C</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-03-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>Epigenetic processes play a key role in orchestrating transcriptional regulation during development. The importance of DNA methylation in fetal brain development is highlighted by the dynamic expression of de novo DNA methyltransferases during the perinatal period and neurodevelopmental deficits associated with mutations in the methyl-CpG binding protein 2 (MECP2) gene. However, our knowledge about the temporal changes to the epigenome during fetal brain development has, to date, been limited. We quantified genome-wide patterns of DNA methylation at ~400,000 sites in 179 human fetal brain samples (100 male, 79 female) spanning 23 to 184 days post-conception. We identified highly significant changes in DNA methylation across fetal brain development at &amp;gt;7% of sites, with an enrichment of loci becoming hypomethylated with fetal age. Sites associated with developmental changes in DNA methylation during fetal brain development were significantly under-represented in promoter regulatory regions but significantly over-represented in regions flanking CpG islands (shores and shelves) and gene bodies. Highly significant differences in DNA methylation were observed between males and females at a number of autosomal sites, with a small number of regions showing sex-specific DNA methylation trajectories across brain development. Weighted gene co-methylation network analysis (WGCNA) revealed discrete modules of co-methylated loci associated with fetal age that are significantly enriched for genes involved in neurodevelopmental processes. This is, to our knowledge, the most extensive study of DNA methylation across human fetal brain development to date, confirming the prenatal period as a time of considerable epigenomic plasticity. A searchable web-resource of DNA methylation trajectories occurring during fetal brain development was developed as part of this work.</gtr:description><gtr:id>F820F626-9B19-4049-B3FA-0741439242C5</gtr:id><gtr:impact>This database has been used by other groups and cited in papers and scientific presentations.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Fetal brain methylomic trajectories</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:url>http://epigenetics.essex.ac.uk/fetalbrain/</gtr:url><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput><gtr:researchDatabaseAndModelOutput><gtr:description>Methylation array data for schizophrenia and control samples.</gtr:description><gtr:id>51A071DE-B786-4F32-ABBD-F3650304C1D6</gtr:id><gtr:impact>Other groups are using their data in their analyses.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Schizophrenia brain methylomic data</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:url>http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE61431</gtr:url><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput><gtr:researchDatabaseAndModelOutput><gtr:description>We characterized DNA methylation quantitative trait loci (mQTLs) in a large collection (n=166) of human fetal brain samples spanning 56-166 days post-conception, identifying &amp;gt;16,000 fetal brain mQTLs. Fetal brain mQTLs are primarily cis-acting, enriched in regulatory chromatin domains and transcription factor binding sites, and show significant overlap with genetic variants also associated with gene expression in the brain. Using tissue from three distinct regions of the adult brain (prefrontal cortex, striatum and cerebellum) we show that most fetal brain mQTLs are developmentally stable, although a subset is characterized by fetal-specific effects. We show that fetal brain mQTLs are enriched amongst risk loci identified in a recent large-scale genome-wide association study (GWAS) of schizophrenia, a severe psychiatric disorder with a hypothesized neurodevelopmental component. Finally, we demonstrate how mQTLs can be used to refine GWAS loci through the identification of discrete sites of variable fetal brain methylation associated with schizophrenia risk variants. mQTLs can be searched in our online database.</gtr:description><gtr:id>2885CEA2-D3B4-4ACD-8A9F-0F401112BEE8</gtr:id><gtr:impact>This has been used by other groups in their analysis of genetic/epigenetic data.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Brain methylation QTL database</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:url>http://epigenetics.essex.ac.uk/mQTL/</gtr:url><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput><gtr:researchDatabaseAndModelOutput><gtr:description>While it is widely acknowledged that the choice of a relevant tissue is imperative for the biological interpretation of epigenome-wide association studies (EWAS), obtaining such samples, particularly in the numbers required to overcome the multiple testing burden of testing loci genome-wide, can be challenging. This is true for studies of brain disorders, such as schizophrenia, Alzheimer's disease and autism, where often alternative, easily obtainable peripheral tissues such as blood or buccal samples are used instead. In order to establish the relevance of associated loci, these are subsequently followed up in available cohorts of brain tissue. Here we introduce an online tool which allows the user to perform this secondary analysis by investigating the correlation of DNA methylation in blood with four brain regions (prefrontal cortex, entorhinal cortex, superior temporal gyrus and cerebellum) from 71-75 matched samples for all probes present on the Illumina 450K Beadchip array.</gtr:description><gtr:id>994B1918-22A9-4C3A-99C8-B2DC7A9872B5</gtr:id><gtr:impact>Several other groups have used and cited this resource in their publications.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Blood Brain DNA Methylation Comparison Tool</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:url>http://epigenetics.essex.ac.uk/bloodbrain/</gtr:url><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Epigenetic processes play a key role in orchestrating transcriptional regulation during development. The importance of DNA methylation in fetal brain development is highlighted by the dynamic expression of de novo DNA methyltransferases during the perinatal period and neurodevelopmental deficits associated with mutations in the methyl-CpG binding protein 2 (MECP2) gene. However, our knowledge about the temporal changes to the epigenome during fetal brain development has, to date, been limited. We quantified genome-wide patterns of DNA methylation at ~400,000 sites in 179 human fetal brain samples (100 male, 79 female) spanning 23 to 184 days post-conception. We identified highly significant changes in DNA methylation across fetal brain development at &amp;gt;7% of sites, with an enrichment of loci becoming hypomethylated with fetal age. Sites associated with developmental changes in DNA methylation during fetal brain development were significantly under-represented in promoter regulatory regions but significantly over-represented in regions flanking CpG islands (shores and shelves) and gene bodies. Highly significant differences in DNA methylation were observed between males and females at a number of autosomal sites, with a small number of regions showing sex-specific DNA methylation trajectories across brain development. Weighted gene co-methylation network analysis (WGCNA) revealed discrete modules of co-methylated loci associated with fetal age that are significantly enriched for genes involved in neurodevelopmental processes. This is, to our knowledge, the most extensive study of DNA methylation across human fetal brain development to date, confirming the prenatal period as a time of considerable epigenomic plasticity. We developed a searchable web-resource of DNA methylation trajectories occurring during fetal brain development.</gtr:description><gtr:id>FB10604A-4F3A-49E6-83FA-C4A45A81496B</gtr:id><gtr:impact>This has been widely used by other groups studying the genomics of brain disorders.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Brain methylation QTL database</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type><gtr:url>http://epigenetics.iop.kcl.ac.uk/fetalbrain/</gtr:url><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>While it is widely acknowledged that the choice of a relevant tissue is imperative for the biological interpretation of epigenome-wide association studies (EWAS), obtaining such samples, particularly in the numbers required to overcome the multiple testing burden of testing loci genome-wide, can be challenging. This is true for studies of brain disorders, such as schizophrenia, Alzheimer's disease and autism, where often alternative, easily obtainable peripheral tissues such as blood or buccal samples are used instead. In order to establish the relevance of associated loci, these are subsequently followed up in available cohorts of brain tissue. Here we introduce an online tool which allows the user to perform this secondary analysis by investigating the correlation of DNA methylation in blood with four brain regions (prefrontal cortex, entorhinal cortex, superior temporal gyrus and cerebellum) from 71-75 matched samples for all probes present on the Illumina 450K Beadchip array.</gtr:description><gtr:id>96F24FF1-3CDB-4E44-A025-E3078E65E2DC</gtr:id><gtr:impact>This has been widely used by other groups assessing epigenetic biomarkers of brain disorders.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>http://epigenetics.essex.ac.uk/bloodbrain/</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type><gtr:url>http://epigenetics.essex.ac.uk/bloodbrain/</gtr:url><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0AF58085-058E-4F70-A43C-87DCF0CF4DE7"><gtr:id>0AF58085-058E-4F70-A43C-87DCF0CF4DE7</gtr:id><gtr:title>An integrated genetic-epigenetic analysis of schizophrenia: evidence for co-localization of genetic associations and differential DNA methylation.</gtr:title><gtr:parentPublicationTitle>Genome biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/73a8bd121700732d13322b944eaf8dff"><gtr:id>73a8bd121700732d13322b944eaf8dff</gtr:id><gtr:otherNames>Hannon E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1474-7596</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CDB9D9C5-515F-45C4-AD67-9D32D5D23E0D"><gtr:id>CDB9D9C5-515F-45C4-AD67-9D32D5D23E0D</gtr:id><gtr:title>Erasure and reestablishment of random allelic expression imbalance after epigenetic reprogramming.</gtr:title><gtr:parentPublicationTitle>RNA (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/27e2914917dbf45c301e8ae636740ee9"><gtr:id>27e2914917dbf45c301e8ae636740ee9</gtr:id><gtr:otherNames>Jeffries AR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1355-8382</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/726B6094-E644-4F8B-BE4D-1879D760EBF3"><gtr:id>726B6094-E644-4F8B-BE4D-1879D760EBF3</gtr:id><gtr:title>Erasure and reestablishment of random allelic expression imbalance after epigenetic reprogramming.</gtr:title><gtr:parentPublicationTitle>RNA (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/27e2914917dbf45c301e8ae636740ee9"><gtr:id>27e2914917dbf45c301e8ae636740ee9</gtr:id><gtr:otherNames>Jeffries AR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1355-8382</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/78E2C014-6994-416F-AE7B-816D08D7784A"><gtr:id>78E2C014-6994-416F-AE7B-816D08D7784A</gtr:id><gtr:title>Collapsed methylation quantitative trait loci analysis for low frequency and rare variants.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7e93a89334f9c50550bc48b84c0467cb"><gtr:id>7e93a89334f9c50550bc48b84c0467cb</gtr:id><gtr:otherNames>Richardson TG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/008B7D49-0A9C-4A34-B0EB-45E3E6B795FF"><gtr:id>008B7D49-0A9C-4A34-B0EB-45E3E6B795FF</gtr:id><gtr:title>Tissue-specific patterns of allelically-skewed DNA methylation.</gtr:title><gtr:parentPublicationTitle>Epigenetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a7b52dfa2214239ad8f998a9194da81c"><gtr:id>a7b52dfa2214239ad8f998a9194da81c</gtr:id><gtr:otherNames>Marzi SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1559-2294</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/91D60F86-3536-4865-A374-C1C827F0D8BC"><gtr:id>91D60F86-3536-4865-A374-C1C827F0D8BC</gtr:id><gtr:title>Methylomic analysis of monozygotic twins discordant for childhood psychotic symptoms.</gtr:title><gtr:parentPublicationTitle>Epigenetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2cedec5bd10a66740e1036ec139eeab1"><gtr:id>2cedec5bd10a66740e1036ec139eeab1</gtr:id><gtr:otherNames>Fisher HL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1559-2294</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A835C3FB-464B-4551-8FD0-E3DBC2F608EA"><gtr:id>A835C3FB-464B-4551-8FD0-E3DBC2F608EA</gtr:id><gtr:title>Methylation QTLs in the developing brain and their enrichment in schizophrenia risk loci.</gtr:title><gtr:parentPublicationTitle>Nature neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/73a8bd121700732d13322b944eaf8dff"><gtr:id>73a8bd121700732d13322b944eaf8dff</gtr:id><gtr:otherNames>Hannon E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1097-6256</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F0769381-E88D-4316-A0C3-B9E2C957CC7E"><gtr:id>F0769381-E88D-4316-A0C3-B9E2C957CC7E</gtr:id><gtr:title>Methylomic profiling of human brain tissue supports a neurodevelopmental origin for schizophrenia.</gtr:title><gtr:parentPublicationTitle>Genome biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6cd860059da8333022783d0f25c6f76b"><gtr:id>6cd860059da8333022783d0f25c6f76b</gtr:id><gtr:otherNames>Pidsley R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1474-7596</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A773086C-91AA-46F0-9381-1AA672D5968A"><gtr:id>A773086C-91AA-46F0-9381-1AA672D5968A</gtr:id><gtr:title>Variation in 5-hydroxymethylcytosine across human cortex and cerebellum.</gtr:title><gtr:parentPublicationTitle>Genome biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/878e2d05b1e177f10ea100a84346398f"><gtr:id>878e2d05b1e177f10ea100a84346398f</gtr:id><gtr:otherNames>Lunnon K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1474-7596</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7E400FB2-4920-4EDC-930A-0BB469154ABD"><gtr:id>7E400FB2-4920-4EDC-930A-0BB469154ABD</gtr:id><gtr:title>Methylomic trajectories across human fetal brain development.</gtr:title><gtr:parentPublicationTitle>Genome research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/23c895ffdbc12d66f477e6b286673f23"><gtr:id>23c895ffdbc12d66f477e6b286673f23</gtr:id><gtr:otherNames>Spiers H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1088-9051</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/420CF5E5-5A39-4C9D-BD4B-1511CE232440"><gtr:id>420CF5E5-5A39-4C9D-BD4B-1511CE232440</gtr:id><gtr:title>Genetic Variation at 16q24.2 is associated with small vessel stroke.</gtr:title><gtr:parentPublicationTitle>Annals of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4ff905ca396cdd019b10c080a5d07bcb"><gtr:id>4ff905ca396cdd019b10c080a5d07bcb</gtr:id><gtr:otherNames>Traylor M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0364-5134</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CF724748-C77A-47FC-8131-EF0532DD6B3F"><gtr:id>CF724748-C77A-47FC-8131-EF0532DD6B3F</gtr:id><gtr:title>Schizophrenia-associated methylomic variation: molecular signatures of disease and polygenic risk burden across multiple brain regions.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6db2fe278c34aa6de97b6a6e12cafcdb"><gtr:id>6db2fe278c34aa6de97b6a6e12cafcdb</gtr:id><gtr:otherNames>Viana J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1B158C73-BFB3-4FF7-AFC6-4A4EA83145A2"><gtr:id>1B158C73-BFB3-4FF7-AFC6-4A4EA83145A2</gtr:id><gtr:title>Epigenomic and transcriptomic signatures of a Klinefelter syndrome (47,XXY) karyotype in the brain.</gtr:title><gtr:parentPublicationTitle>Epigenetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6db2fe278c34aa6de97b6a6e12cafcdb"><gtr:id>6db2fe278c34aa6de97b6a6e12cafcdb</gtr:id><gtr:otherNames>Viana J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1559-2294</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D42FD264-6419-40AD-8B6A-ADFBEABFE6E9"><gtr:id>D42FD264-6419-40AD-8B6A-ADFBEABFE6E9</gtr:id><gtr:title>Genetic variants near MLST8 and DHX57 affect the epigenetic age of the cerebellum.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a599c3b84fc5116f271b0e9778babbce"><gtr:id>a599c3b84fc5116f271b0e9778babbce</gtr:id><gtr:otherNames>Lu AT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3EEB9319-B19D-48EC-BF45-94B358C38EB8"><gtr:id>3EEB9319-B19D-48EC-BF45-94B358C38EB8</gtr:id><gtr:title>Interindividual methylomic variation across blood, cortex, and cerebellum: implications for epigenetic studies of neurological and neuropsychiatric phenotypes.</gtr:title><gtr:parentPublicationTitle>Epigenetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/73a8bd121700732d13322b944eaf8dff"><gtr:id>73a8bd121700732d13322b944eaf8dff</gtr:id><gtr:otherNames>Hannon E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1559-2294</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/49733544-9BDC-4BE6-8ECA-AF5509CF67DD"><gtr:id>49733544-9BDC-4BE6-8ECA-AF5509CF67DD</gtr:id><gtr:title>Epigenetics in health and disease: heralding the EWAS era.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ace9be6c0a7b34251b6ae9bb97c53f7f"><gtr:id>ace9be6c0a7b34251b6ae9bb97c53f7f</gtr:id><gtr:otherNames>Murphy TM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/K013807/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>3C193D18-12BD-4B15-8347-037BA623E0FF</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Mental Health</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>